South Africa Pulmonary Arterial Hypertension Market Size & Outlook

The pulmonary arterial hypertension market in South Africa is expected to reach a projected revenue of US$ 299.9 million by 2030. A compound annual growth rate of 6.4% is expected of South Africa pulmonary arterial hypertension market from 2025 to 2030.
Revenue, 2024 (US$M)
$208.1
Forecast, 2030 (US$M)
$299.9
CAGR, 2025 - 2030
6.4%
Report Coverage
South Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

South Africa pulmonary arterial hypertension market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

South Africa pulmonary arterial hypertension market highlights

  • The South Africa pulmonary arterial hypertension market generated a revenue of USD 208.1 million in 2024 and is expected to reach USD 299.9 million by 2030.
  • The South Africa market is expected to grow at a CAGR of 6.4% from 2025 to 2030.
  • In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2024.
  • SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.


Pulmonary arterial hypertension market data book summary

Market revenue in 2024USD 208.1 million
Market revenue in 2030USD 299.9 million
Growth rate6.4% (CAGR from 2025 to 2030)
Largest segmentProstacyclin and prostacyclin analogs
Fastest growing segmentSGC Stimulators
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationEndothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
Key market players worldwideUnited Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd


Other key industry trends

  • In terms of revenue, South Africa accounted for 2.6% of the global pulmonary arterial hypertension market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, South Africa pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
  • Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 186.7 million by 2030.

Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 49.69% in 2024. Horizon Databook has segmented the South Africa pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.


Governments and healthcare organizations are undertaking initiatives to improve the healthcare facilities in the respective MEA countries. South Africa PAH market stood at USD 42.6 million in 2015. Economic development of South Africa and the presence of high unmet healthcare needs are some primary growth drivers of this market.

High burden of associated diseases such as HIV which vital factor for development of PAH. Expected growth in healthcare spending and the resultant rising demand for advanced healthcare treatments is anticipated to boost the market during the forecast period. Moreover, the government of the country is directing efforts toward regulating the healthcare industry in South Africa.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Pulmonary Arterial Hypertension Market Companies

Name Profile # Employees HQ Website
Sandoz Group AG ADR View profile - - -
GlaxoSmithKline View profile 10001+ London, England, United Kingdom, Europe http://www.gsk.com
United Therapeutics Corp View profile 1168 1000 Spring Street, Silver Spring, MD, United States, 20910 https://www.unither.com
Viatris Inc View profile 38000 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 https://www.viatris.com
Gilead Sciences Inc View profile 18000 333 Lakeside Drive, Foster, CA, United States, 94404 https://www.gilead.com
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com
Bayer AG View profile 99723 Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 https://www.bayer.com
Lupin View profile 10001+ Mumbai, Maharashtra, India, Asia https://www.lupin.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

South Africa pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)

South Africa Pulmonary Arterial Hypertension Market Outlook Share, 2024 & 2030 (US$M)

South Africa pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online